A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy
S. Park, M. H. Lee, M. Seong, S. T. Kim, J. H. Kang, B. C. Cho, K. H. Lee, E. K. Cho, J. M. Sun, S. H. Lee, J. S. Ahn, K. Park, M. J. Ahn
Dive into the research topics of 'A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy'. Together they form a unique fingerprint.